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Abstract
Background: Tuberculosis (TB) remains one of the most deadly infectious diseases. One-third to one-fourth of the
human population is estimated to be infected with Mycobacterium tuberculosis (Mtb) without showing clinical
symptoms, a condition called latent TB infection (LTBI). Diagnosis of Mtb infection is based on the immune response to a
mixture of mycobacterial antigens (PPD) or to Mtb specific ESAT-6/CFP10 antigens (IGRA), highly expressed during the
initial phase of infection. However, the immune response to PPD and IGRA antigens has a low power to discriminate
between LTBI and PTB. The T-cell response to a group of so-called latency (DosR-regulon-encoded) and Resuscitation
Promoting (Rpf) antigens of Mtb has been proved to be significantly higher in LTBI compared to active TB across many
populations, suggesting their potential use as biomarkers to differentiate latent from active TB.
Methods: PBMCs from a group LTBI (n = 20) and pulmonary TB patients (PTB, n = 21) from an endemic community for
TB of the city of Medellín, Colombia, were in vitro stimulated for 7 days with DosR- (Rv1737c, Rv2029c, and Rv2628), Rpf-
(Rv0867c and Rv2389c), the recombinant fusion protein ESAT-6-CFP10 (E6-C10)-, or PPD-antigen. The induced IFNγ levels
detectable in the supernatants of the antigen-stimulated cells were then used to calculate specificity and sensitivity in
discriminating LTBI from PTB, using different statistical approaches.
Results: IFNγ production in response to DosR and Rpf antigens was significantly higher in LTBI compared to PTB. ROC
curve analyses of IFNγ production allowed differentiation of LTBI from PTB with areas under the curve higher than 0.70.
Furthermore, Multiple Correspondence Analysis (MCA) revealed that LTBI is associated with higher levels of IFNγ in
response to the different antigens compared to PTB. Analysis based on decision trees showed that the IFNγ levels
produced in response to Rv2029c was the leading variable that best-classified disease status. Finally, logistic regression
analysis predicted that IFNγ produced by PBMCs in response to E6-C10, Rv2029c, Rv0867c (RpfA) and Rv2389c (RpfA)
antigens correlates best with the probability of being latently infected.
Conclusions: The Mtb antigens E6-C10, Rv2029c (PfkB), Rv0867c (RpfA) and Rv2389c (RpfA), may be potential candidates
to discriminate LTBI from PTB.
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Background
Tuberculosis (TB) continues to be one of the deadliest
infectious diseases. In 2015 WHO reported an increase
in the world prevalence and mortality rate of active tu-
berculosis (TB) disease cases [1], particularly in the de-
veloping world. Latent TB infection (LTBI), defined as
the absence of clinical symptomatology in the presence
of infection, affects an estimated one-third to one-fourth
of the human population [2], and as a result of reactiva-
tion disease represents the primary source of active TB.
LTBI is traditionally identified as a positive reaction (>5–
10 mm induration) in response to the intradermal injection
of a protein purified extract of Mycobacterium tuberculosis
(Mtb), named tuberculin | [3]. Although sensitive, the spe-
cificity of the intradermal reaction is compromised by pre-
vious vaccination with M. bovis BCG and/or infection with
some non-tuberculous mycobacteria (NTM) [4]. More re-
cently, the Interferon Gamma Release Assays (IGRAs) have
contributed to a higher specificity in detection of Mtb in-
fection since these assays utilize proteins encoded in the
Mtb, but not in the BCG genome, such as ESAT-6 and
CFP10 [5–8]. Nevertheless, both assays have demonstrated
a low predictive value for progression to the active forms
of TB [9, 10].
During the last few years, in vivo and in vitro evidence
has indicated that Mtb adapts its transcriptional signa-
ture to the microenvironmental conditions posed by the
host cells, such as macrophages and dendritic cells, and
in granulomas of the infected host [11–14]. In addition,
these transcriptional changes seem to be necessary for
infection establishment [11, 12]. In conditions such as
hypoxia, acidic pH, nutrient starvation, and high con-
centrations of oxygen (ROIs) and nitrogen (RNIs) react-
ive intermediates and CO2 that may all be present inside
granulomas [15, 16], Mtb requires a group of approxi-
mately 50 genes known as the dosR regulon [11, 13, 17]
to survive and enter dormancy. Indeed, the expression
of dosR regulon encoded genes has been associated with
the non-replicative persistence of Mtb [11, 12], showing
that some members of this regulon are playing an im-
portant role in the maintenance of the latency condition.
On the other hand, a family of five genes able to induce
resuscitation of dormant bacilli, termed resuscitation-
promoting factors (rpf ), has also been identified in the
Mtb genome [18]. It has been described that the proteins
encoded by the rpf genes (rpfA-E) are capable of stimu-
lating the mycobacterial growth of non-replicating cells
obtained in vitro [18, 19] and play a significant role in
the in vivo persistence and reactivation of chronic infec-
tion in mice [20, 21]. Additionally, ex vivo studies, have
demonstrated that Rpf proteins increased the recovery
of Mtb from sputum of the patient with active TB [22]
and improved the sensitivity of culture-based Mtb test in
samples that require long culture times [23].
Given the interest in proteins encoded by the dosR
regulon and the rpf genes, the cellular immune response
to some of these members has been studied in different
human populations of Africa, Asia, Europe, and Amer-
ica, demonstrating significantly increased responses of
LTBI individuals compared to active TB [24–36]. Our
studies in a TB endemic community in the city of
Medellín, Colombia, have also provided evidence that
the dosR encoded Rv1737c (NarK, nitrate reductase),
Rv2029c (PFKB, phosphofructokinase B), the hypothet-
ical protein Rv2628, and the resuscitation-promoting
factors (Rpf), Rv0867c (RpfA) and Rv2389c (RpfD), in-
duced higher production of IFNγ and a higher frequency
of T-cells with a CD45RO+CD27+ (Tcm) phenotype in
7-day stimulation assays of peripheral blood mono-
nuclear cells (PBMCs) of LTBI compared to active TB
[29, 30, 33]. Interestingly, this higher response of PBMC
from LTBI compared to active TB to Rv1737c, Rv2029c
and Rv2628 has also been observed in Africa, Asia, Eur-
ope, India and Brazil [24–27, 37], suggesting an immune
response independent of the human genetic and envir-
onmental background, and possibly of the circulating
Mtb strains, and thus suggesting the presence of a preva-
lent immune response to DosR antigens in LTBI.
Given the problems of sensitivity and specificity associ-
ated with the immune response to ESAT-6 and CFP10
Mtb antigens, the search for immune response biomarkers
that more efficiently classify LTBI from active TB is a top
priority for the prevalence and incidence of active TB to
be reduced. In this study, using variables of the immune
response, Receiver Operating Characteristics (ROC
curves), CHi-squared Automatic Interaction Detection
(CHAID) and logistic regression (LR), we found that the
Rv2029c antigen of Mtb is a novel classifier of LTBI vs. ac-
tive TB with high specificity and sensitivity.
Methods
Study population
The study population included two groups of individuals:
20 household contacts (HHC) of recently diagnosed (within
2 weeks) pulmonary tuberculosis patients (PTB), and 21
PTB. The HHC were selected from a previous cohort of
HHC from PTB, based on their positive response (≥22 pg/
ml) to the CFP10 antigen of Mtb and the absence of clinical
symptoms compatible with clinical TB [38]. The selected
HHC have remained healthy for more than 5 years after
the incident case diagnostics (long-term LTBI, ltLTBI), and
have not received anti-TB treatment accordingly to the Co-
lombian Minister of Health regulations. The active TB sta-
tus was confirmed microscopically, by detection of acid-fast
bacilli (AFB) on sputum smears at the local TB control pro-
gram’s laboratories, for all TB cases included in the study.
The Mycobacterium bovis BCG vaccination status was de-
termined based on the identification of the typical scar left
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after previous vaccination. The blood samples collected
from the participants were taken after reading and accept-
ance of the informed consent forms. This study was
approved by the Ethics Committee, Instituto de Investiga-
ciones Médicas, Facultad de Medicina, Universidad de
Antioquia (Medellín-Colombia).
Regents
RPMI-1640 and Dulbecco’s PBS (DPBS) were obtained
from GIBCO (Grand Island, NY); Ficoll-Hypaque, and
penicillin-streptomycin solution from Bio-Whittaker
(Walkersville, MD); dimethyl sulphoxide (DMSO); pooled
human serum (PHS) from Invitrogen (Brown Deer, WI; Eu-
gene, OR).
Mycobacterial antigens
Three dosR regulon-encoded (Rv1737c, Rv2029c, Rv2628),
two Resuscitation Promoting (Rv0867c and Rv2389c) anti-
gens from Mycobacterium tuberculosis (Mtb), recognized
as immunogenic in a previous study [29], and the RD1 fu-
sion Protein ESAT6-CFP10 (E6-C10) were used in the
present study. The recombinant proteins were produced
and QC-ed by CLMCF and THMO. The production,
quality control, preparation and storage of the antigens
was previously described [24, 39]. Briefly, genes were amp-
lified by PCR and cloned by Gateway Technology (Invitro-
gen, San Diego, CA) in a bacterial expression vector
containing an N-terminal histidine tag. The proteins were
overexpressed in Escherichia coli BL21(DE3) and purified,
as described previously [40]. Purity and size were checked
by gel electrophoresis and Western blotting with anti-His
antibodies and anti-E. coli antibodies. Residual endotoxin
levels were determined by a Limulus amebocyte lysate
assay (Cambrex) and were found to be below 50 IU/mg
recombinant protein. Recombinant antigens were freeze-
dried and shipped at ambient temperature to the Colom-
bian research site, prepared as described [40] aliquoted
and stored at −80 °C until further use. The purified pro-
tein extract (RT50) (PPD) from Staten Serum Institute
(Copenhagen, Denmark) was also used in this study.
Isolation of peripheral blood mononuclear cells (PBMCs)
and culture conditions
The procedure to obtain and culture conditions for periph-
eral blood mononuclear cells (PBMCs) were previously de-
scribed [29, 30, 33]. Briefly, PBMCs were collected from
sodium heparin anticoagulated venous blood (10 ml) and
separated by Ficoll-Hypaque density gradient centrifuga-
tion. PBMC were washed twice in DPBS, counted in a
hemocytometer and cell viability determined by trypan blue
exclusion (>94% for all experiments). 1.5 × 105 cells/well
were seeded in triplicate in 96-well U-bottom plates (Corn-
ing Costar Inc., Corning, NY), in a final volume of 200 μl/
well of RPMI-1640 supplemented with 100 U/ml of
penicillin, 100 μg/ml of streptomycin, and 10% human
pooled serum (PHS). Cells were cultured in the presence or
absence of 5 μg/ml (final concentration) of PPD, the fusion
protein E6-C10, or the selected DosR and Rpf antigens. Cell
cultures were incubated at 37 °C, 5% de CO2, and 90% rela-
tive humidity for 168 h (7-days). Dead cells were deter-
mined by staining with 7AAD (Thermo Fisher Scientific,
Carlsbad, CA). The number of viable cells at the end of the
culture period was >80% for all experiments.
IFNγ quantitation
Quantitation of IFNγ present in the supernatants of
non-stimulated and antigen-stimulated PBMCs was per-
formed by the Luminex technology using a commercial
kit from Millipore (Millipore, Billerica, MA, USA), and a
Luminex reader (Bioplex 200 Analyzer, BioRad, Labora-
tories Inc), as previously reported [29].
Statistical analysis
The IFNγ levels in response to antigens were expressed as
net values. The Shapiro-Wilk test was used to test normal-
ity in data distribution. The difference in the IFNγ levels
between LTBI and PTB was determined by the non-
parametric U-Mann Whitney test. The differences in gen-
der and BCG scar between LTBI and PTB was tested by
the Chi-square statistics. The capacity of IFNγ levels to dis-
criminate between LTBI and PTB was tested using Receiver
Operating Characteristics (ROC) curves. The cut-off level
of IFNγ that determines the highest sensitivity and specifi-
city for each of the antigens was identified by the Youden
index (calculated using the formula: sensitivity + specificity
- 1) [41]. The cut-off levels were used to categorize the high
and low responses to IFNγ to each one of the antigens, and
later to determine the antigens predictive capacity for dis-
ease status (LTBI and PTB). For this purpose, multivariate
approaches were used. The multiple correspondence ana-
lysis (MCA) was used to determine the response profiles to
each antigen based on disease status while the CHi-squared
Automatic Interaction Detection (CHAID) [42], was used
to determine the antigens that better influence the predic-
tion of being LTBI or PTB. To quantify the degree of asso-
ciation and the influence of the IFNγ response levels of
each antigen on the disease status, a logistic regression
model was built using a 25 LTBI and PTB subsample that
was further validated with a 16 LTBI and PTB subsample.
For model estimation, the Bootstrapping method with 100
repetitions was used including the first subsample and all
antigens. For model validation, the coefficients obtained
with the first 25 subsample (16 LTBI and 9 PTB) were used,
and the calibration was evaluated by using the percentage
of correct classification (87.5%), the Kappa statistic (0.75
CI95%: 0.42–1.0), and the AUC (Area Under the Curve,
0,94 (IC95%: 0,83–1,0) with its respective confidence inter-
val. The Forward method was also explored to get
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information on the top antigens to predict active disease.
Statistical analyses were performed using the Statistic Pack-
age for Social Science Program (SPSS version 21.0, Chicago,




The median age of the LTBI group was 38.5-years old (IQR
= 26.75–52.75), 55% males, and 80% had a visible BCG-
scar. The group of individuals with active pulmonary TB
(PTB) had a median age of 28-years old (IQR = 24–41), and
71% were BCG-scar positive. No significant differences in
age, gender or BCG-scar positivity were observed between
both groups of individuals (data not shown).
Capacity of the individual antigens to discriminate
between LTBI and PTB disease status
The utilization of RD-1 antigens of Mtb in the commer-
cially available IGRAs has contributed to a higher
specificity for infection detection in comparison to the
tuberculin skin test. Similar to the TST, however, IGRAs
cannot discriminate between LTBI and active TB [43–
45]. Therefore, the identification of new (host and/or
pathogen) biomarkers that discriminate between latent
and active TB is a necessity [3]. Thus, we determined
the in vitro production of IFNγ by PBMCs from LTBI
and PTB in response to selected Mtb DosR (Rv1737c,
Rv2029c and Rv2628) and Rpf (Rv0867c and Rv2389c)
antigens [29, 30, 33] using 7-day PMBC stimulation
assay. LTBI individuals displayed significantly higher
levels of IFNγ in response to PPD (p = 0.004), E6-C10 (p
< 0.001), Rv1737c (p = 0.004), Rv2029c (p < 0.001),
Rv2628 (p = 0.017), RpfA (p = 0.009) and RpfD (p =
0.013) (Fig. 1; Table 1 and Additional file 1: Table S1).
Then, ROC curves were used to evaluate the cap-
acity of the antigen specifically induced IFNγ levels to
classify LTBI from PTB individuals and to determine
the optimal cutoff for each antigen. ROC curves
showed that IFNγ production in response to the stud-
ied antigens allowed to differentiate LTBI from PTB



































































Fig. 1 Comparison of the IFNγ levels in LTBI and PTB in response to RD-1 Esat6-Cfp10 (E6-C10), DosR and Rpf antigens. PBMCs (1 × 105) were cultured
for 7 days, in the presence or absence of PPD, E6-C10 and the DosR and Rpf antigens. IFNγ levels in LTBI (orange circles) and PTB (blue circles)
were determined by Luminex. Mann-Whitney U-test was used to calculate statistical differences between groups and p-values are shown in the
graphs (*, p < 0.05; **, p < 0.01; ***, p < 0.001)
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moreover, from the analyses the Rv2029c antigen was
found to have the highest contribution to the higher
discrimination (Table 1).
Utility of antigens combinations to discriminate between
LTBI and PTB
To fully evaluate how the IFNγ response to all antigens
could improve the discriminatory capacity between LTBI
and PTB, we used multiple correspondence analysis
(MCA), a technique for nominal categorical data used to
detect and represent underlying structures in a dataset
[46]. The MCA results revealed that LTBI individuals
are associated with a profile characterized by higher
levels of IFNγ in response to the different antigens while
PTB are associated with a lower IFNγ profile (Fig. 2).
To identify the variable that better predict the dis-
ease status (LTBI or PTB), we performed an analysis
based on decision trees (CHAID), to determine which
antigens better influence the prediction of being LTBI
or PTB. This analysis showed that the higher IFNγ
levels produced in response to the DosR antigen
Rv2029c (PfkB), is the antigen that best predicted dis-
ease status (Fig. 3). The individuals that presented
with higher levels of IFNγ in response to Rv2029c
display a higher probability of being latently infected
(78.3%; Node 1, Fig. 3), while individuals that pro-
duced low levels of IFNγ in response to Rv2029c dis-
played a higher probability of being PTB (88.9%;
Node 2, Fig. 3). Also, this method correctly classified
82.9% of the individuals.
To confirm the single antigen that best differenti-
ates between PTB and LTBI, we used the Forward
selection method of stepwise regression. The results
(data not shown), confirmed Rv2029c as the antigen
that best discriminates between those two condi-
tions. Moreover, employing a cross-validation strat-
egy as described in the Statistical Analyses section,
this analysis showed that a combination of four anti-
gens E6-C10, Rv2029c, Rv0867c, and Rv2389c, are
those that provide the greatest discrimination be-
tween LTBI and PTB (Table 2). Using this model, it
was possible to construct a prediction rule allowing
separation of latent from active TB (Classification
score: −2,35 + (0,42 x PPD) + (1,90 x E6C10R) + (0,48
x Rv1737cR) + (2,45 x Rv2029cR) + (0,138 x
Rv2628R) + (1,86 x Rv0867cR) – (1,87 x Rv2389cR)
Probability of LTB: 1(1 + e–classification score)). The
validation of this model in a sub-sample (n = 16),
showed a high capacity to differentiate LTBI from
PTB with an AUC = 0,94 (95% CI:0.83–1.0). Add-
itionally, this model correctly classified 85,7% of the
LTBI and 88,9% of the PTB.
Table 1 Abilities of the IFNγ in response to PPD, E6-C10, DosR and Rpf antigens to discriminate between LTBI and PTB
Antigens PTB Median (IQR) HHC-LTBI Median (IQR) p-value* AUC (95% CI) Cut-off (pg/ml) Sensitivity (%) Specificity (%)
DosR
Rv1737c 70.7 (18.8–664.2) 1742.0 (209.2–2528.0) 0.0041 0.76 (0.60–0.92) 1014.96 65.0 90.5
Rv2029c 233.4 (38.9–961.3) 2421.0 (1182.0–4426.0) 0.0003 0.82 (0.69–0.96) 763.15 90.0 76.2
Rv2628 452.3 (29.1–1363.0) 2489.0 (281.0–7006.0) 0.0173 0.72 (0.55–0.88) 1569.41 65.0 81.0
Rpf
Rv0867c 121.8 (19.3–437.2) 576.8 (181.0–1224.0) 0.0091 0.74 (0.58–0.89) 454.89 65.0 81.0
Rv2389c 15.5 (6.3–200.3) 349.5 (74.72–932.6) 0.0126 0.73 (0.57–0.89) 28.36 85.0 61.9
Control
E6-C10 56.5 (2.4–1027.0) 2623.0 (461.0–6761.0) 0.0006 0.80 (0.66–0.94) 1070.36 75.0 81.0
PPD 2355.0 (401.3–3949.0) 5453.0 (2137.0–18,874.0) 0.0042 0.76 (0.60–0.91) 4464.11 65.0 86.0
IQR Interquartile Range. AUC Area Under the ROC Curve. CI Confidence Interval
*p-value for the Mann-Whitney test
Fig. 2 Multiple correspondence analysis for the IFNγ levels in response
to RD-1 Esat6-Cfp10 (E6-C10), DosR and Rpf antigens in LTBI and PTB
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Discussion
The immune response to PPD and IGRA antigens has a
low power to discriminate between LTBI and PTB [44, 45].
Indeed, the predictive value of IGRAs for progression to
TB disease is low and slightly but not significantly higher
than that of the TST [9, 45]. Therefore, new biomarkers are
urgently needed to facilitate the diagnosis of LTBI [3].
Herein we have evaluated the potential of the Mtb an-
tigens E6-C10, the DosR Rv1737c, Rv2029c, and Rv2628,
and the Rpf RpfA and RpfD to discriminate latent TB
infection from active TB. The DosR antigens evaluated
in the present study induced a higher production of
IFNγ in stimulated PBMCs from LTBI compared to
PTB. Also, the production of IFNγ to DosR antigens
showed a high probability to discriminate disease status
(AUC >0.70). Different studies, including ours, indicate
that LTBI preferentially recognizes DosR antigens
compared to PTB in different human populations [24–
26, 29, 30, 32, 33, 35, 37]. In this study, Rv2029c (pfkB)
was included in the model that better-predicted disease
status, with a correct classification of 78.3% of LTBI and
88.9% of PTB, according to the analysis based on deci-
sion trees (CHAID). Additionally, the logistic regression
analysis using the forward method also showed Rv2029c
as the antigen that better discriminates between those
two conditions (data not shown).
Recent studies have highlighted the immunological im-
portance to Rv2029c. Vaccination of mice with DosR anti-
gens, including Rv2029c induced strong humoral and/or
cellular Th1-type (interleukin-2 and gamma interferon) im-
mune responses [47]. In humans, a stronger response to
Rv2029c in LTBI compared to PTB has been reported in
the Netherlands [24], Africa [25, 35], Japan [26], China [36],
Brazil [27], and Colombia [29, 30, 33]. Remarkably, in a
one-year longitudinal study in Brazilian subjects recently
exposed to TB, classified by IGRA and TST positivity,
PBMCs stimulation with latency antigens, including
Rv2029c, it was found that combining the IFNγ responders
to Rv2029c, Rv2031c plus Rv2034 detected 90.3% of IGRA-
RD1(+) and 66.7% of TST(+) contacts, while 95% were
identified by classifying them as TST(+) IGRA-RD(+) and
11% as TST(−) IGRA(−). Moreover, in the follow-up, the
TST converters also demonstrated an IFNγ conversion to
Rv2029c and Rv2031c, whereas the only TB incident case
was detected via IGRA-Rv2029c and TST previous to de-
veloping TB [25]. In another study, the LTBI diagnostic per-
formance of Rv2029c was higher than Rv2628 and Rv1813c
by ROC evaluation [36]. Furthermore, in a study in of the
in vitro immune response to the DosR antigens Rv1733c,
Rv2029c, Rv2628 before and after 2-week anti-tuberculosis
treatment in Ghanaians PTB, it was found that the second
week of effective chemotherapy was characterized by a gen-
eral increase in cytokine response to Mtb-specific antigens
suggesting improvement in cellular response to therapy
[48]. Thus, our studies strengthen the observation that
Rv2029c may constitute a relevant biomarker of LTBI. Be-
sides, our findings that Rv2029 was included in the model
of logistic regression analysis that best predicted latent and
active TB, along with E6-C10 and Rpf antigens, may suggest
that Rv2029c is a useful diagnostic candidate who might in-
crease the capacity to discriminate between LTBI and PTB
in combination with antigens currently used as such as
ESAT-6 and CFP-10, even though much larger studies need
to be performed to validate the present results.
Fig. 3 Decision-tree diagram based on CHAID analysis, showing the
antigens that better influence the prediction of being LTBI or PTB
Table 2 Capacity of PPD, E6C10, DosR and Rpf antigens to







Step 1 PPD 0.424 34.863b 0.139b −42.725 76.794
E6C10 1.899 43.275b 0.025b −62.260 119.469
Rv1737c 0.478 30.405b 0.152b −41.714 76.074
Rv2029c 2.454 40.806b 0.038b −39.811 151.793
Rv2628 0.138 32.905b 0.253b −77.272 41.945
Rv0867c 1.860 35.250b 0.025b −36.482 107.89
Rv2389c −1.865 39.777b 0.025b −132.135 73.181
Constant −2.354 31.571b 0.127b −95.683 −0.056
aBoostrap results based on 100 bootstrap samples, bBased on 78 samples; SE
Standard Error, CI Confidence Interval, Sig Significance
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Similar to the DosR antigens, the Rpf antigens (RpfA
and RpfD) induced a higher production of IFNγ in stim-
ulated PBMCs from LTBI compared to PTB and showed
a high probability to discriminate disease status (AUC
>0.70). Additionally, these antigens were included in the
model that predicted the disease status. The results ob-
tained in this study are consistent with those reported
by Chegou and colleagues [49], who found that Rv0867c
(RpfA) and Rv2389c (RpfD) were included in antigen
combinations discriminating between HHC and PTB. It
has been reported that rpf genes are differentially
expressed at different growth stages, and stress condi-
tions, with rpfA and rpfD, mainly expressed during early
resuscitation [50]. Studies conducted in different human
population, including ours, indicate that an immune re-
sponse to RpfA and RpfD antigens has been preferen-
tially found in LTBI suggesting that the immune
response to Rpf antigens may play a protective role
against bacilli reactivation [29, 34, 35]. It has been sug-
gested that the bacilli may indeed still be replicating but
are controlled by the host immune response during LTBI
infection [51, 52]. So, the host may be exposed to anti-
gens from the different metabolic states of Mtb in vivo,
and the response to these antigens may be detected in
in-vitro stimulation assays. Thus, our results suggest that
RpfA and RpD antigens also could be added to current
diagnostic tests to improve the capacity to discriminate
between LTBI and PTB.
On the other hand, and somewhat unexpectedly, our
results show that the fusion protein E6-C10 induced a
higher production of IFNγ in stimulated PBMCs from
LTBI compared to PTB and that the production of IFNγ
to E6-C10 antigens showed a high probability to differ-
entiate between LTBI and PTB (AUC >0.70). Although
E6-C10 was not selected as the best predictor of the dis-
ease status, according to the analysis based on decision
trees (CHAID) and the logistic regression analysis using
the forward method, E6-C10 was included in the model
that better discriminates between LTBI and PTB. This
result is consistent with those reported by Chegou and
colleagues [49], who found that E6-C10 was included in
the most of the antigen combinations discriminating be-
tween presence and absence of TB disease. ESAT-6 and
CFP-10 antigens are encoded by genes located within
the region of difference 1 (RD1) of the Mtb genome, a
chromosomal segment absent in the BCG vaccine strains
and most of the NTM [7, 8]. So, the utilization of these
antigens in the commercially available IGRAs has con-
tributed to a higher specificity for infection detection in
comparison to the tuberculin skin test [44, 45]. The RD-
1 antigens are described to be secreted during Mtb
active replication [6, 53]. Additionally, it has been de-
scribed that the expression of genes encoding early stage
proteins such as ESAT-6 is repressed during the
stationary phase of Mtb growth in the lungs of chronic-
ally infected mice [54], suggesting that they might not be
expressed optimally during later stages of Mtb infection
and likely play a much less dominant role during LTBI
than proteins from the DosR regulón or Rpf antigens.
Collectively these results suggest that the use the DosR
antigen Rv2029c and RpfA and Rpf in T cell assays
(IGRAs), in addition to E6-C10, could enhance the abil-
ity to differentiate LTBI from TB disease especially in a
high-burden setting where a mixture of recent and old
infections is commonly found [38].
Our study presents some limitations such as the
small sample size which therefore should be extended
and validated in a more significant number of partici-
pants and different human populations; the use of a
7-day in vitro culture assay rather than a more user
friendly assay; the absence of a healthy control group;
and the lack of longitudinal evaluation of progression
to disease. Although a recent infection is more de-
tectable in a short-term stimulation, it has been ar-
gued that long-term stimulation is more sensitive to
the detection of LTBI than those with short-term
stimulation times particularly in regions of high
endemicity in which a mixture of recent and old in-
fections are frequently found [32, 55, 56]. Thus, long-
term stimulation may be better to measure central
memory T-cell responses [55–57]. By using long-term
stimulation conditions, our group has previously re-
ported the enhanced ability to detect Tcm cells
(CD45RO+CD27+) in response to mycobacterial anti-
gens [29, 30, 58, 59]. For that reason, we used long-
term cultures to define the LTBI status and compared
the immune response between the study groups. As
previously pointed out, future works should include a
prospective evaluation the antigens and host markers
identified in this study, using larger sample size, dif-
ferent geographic settings and using preferably short-
term assays to detect effector cell responses. Future
studies should also evaluate the antigens and host
markers in different study populations as such as
children, individuals with immune suppression (e.g.,
due to HIV coinfection, therapy with TNF-α inhibi-
tors, or due to type 2 diabetes), in TB patients after
anti-TB therapy, in patients with extrapulmonary TB,
and also in individuals with other lung diseases [49].
Conclusions
We found that in an endemic community for TB of
the city of Medellín, Colombia, human PBMC re-
sponses to E6-C10, the Mtb DosR antigens Rv2029c
(PFKB) and the Rpf antigens, RpfA and RpfD, can
discriminate latent from active TB, and may be poten-
tial candidates for improved diagnostic tests as well
as anti-tuberculous vaccines.
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